Peptide Science Basics: Evidence-First Education on Peptides and Health

Bottom line Peptides are having a moment — promoted by influencers, wellness clinics, and even the Secretary of Health and Human Services. But much of what you hear about them doesn't survive contact with the evidence. Drawing on an October 19, 2026 KFF Health News investigation, here are four widely repeated claims about peptides that fall apart under scrutiny — and the one legitimate point buried underneath the hype. "Peptides aren't drugs" This one comes from Gary Brecka,

Bottom line On October 14, 2026, the FDA and the Department of Health and Human Services submitted an "interim access policy for compounding using certain peptides" to the White House for review. If finalized, it would let licensed compounding pharmacies make and sell certain unapproved peptides — reportedly including BPC-157 — under temporary enforcement discretion. It would not make any peptide FDA-approved, and FDA's own scientists advised against the move at a July meetin

Bottom line On September 18, 2026, the FDA sent a warning letter to Empower Clinic Services, LLC, doing business as Empower Pharmacy in Houston, Texas — one of the largest compounding pharmacies in the United States. The letter alleges that Empower mass-produced compounded versions of the GLP-1 drugs tirzepatide and semaglutide (with added vitamins) that were essentially copies of FDA-approved products, which federal law does not allow traditional compounding pharmacies to ma

Bottom line Oxytocin earned its "love hormone" nickname honestly — it is a real peptide hormone central to childbirth, breastfeeding, and social bonding. But the popular claims went much further than the evidence: that a nasal spray could make you more trusting, more sociable, or treat autism. The largest clinical trial, published in the New England Journal of Medicine in 2021, found no benefit for autism, and years of follow-up studies produced mixed or negative results. Tha

Bottom line MOTS-c — a mitochondrial-derived peptide with a large animal-research literature and zero human efficacy data — is now in its first interventional human trial. The Phase 2a study (NCT07505745, "MOTS-MET") is randomized, double-blind, and placebo-controlled: 120 adults with prediabetes and overweight or obesity receive either MOTS-c or placebo by daily subcutaneous injection for 12 weeks, with insulin sensitivity as the primary endpoint. The trial is currently recr

## Bottom line In mid-September 2026, Australia's medicines regulator revealed that a patient tore their esophagus after using an unapproved product sold as retatrutide. Testing found the vial contained no retatrutide at all — just undeclared semaglutide at roughly eight times the level found in TGA-assessed approved semaglutide products. Separately, independent lab testing of three products sold as retatrutide found actual contents ranging from 51% to 190% of the labeled dos

Bottom line On September 1, 2026, Rep. Nancy Mace (S.C.) introduced the first federal bill written specifically about peptide therapies: the Providing Evidence-based Peptide Therapies to Improve Delivery and Expanded Services for Veterans Act — the PEPTIDES for Veterans Act. It would direct the Department of Veterans Affairs to review peptide regulations, study peptide therapies for conditions including chronic pain and mental health, and — only if the evidence supports it —

Bottom line Online communities often call the combination of BPC-157 and TB-500 the “Wolverine stack,” implying unusually fast healing after tendon injuries, surgery, cartilage procedures, muscle strains, or demanding training. That name is marketing language, not a clinical category. The available evidence does not establish that combining BPC-157 and TB-500 safely accelerates healing in people after surgery or orthopedic injury. BPC-157 has extensive preclinical literature

Bottom line In July 2026, FDA’s Pharmacy Compounding Advisory Committee (PCAC) considered several peptide-related bulk drug substances for possible inclusion on the federal 503A Bulks List. The committee voted to recommend inclusion for specified forms of BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax, while voting against emideltide, also called DSIP. That vote is important, but it is not the final word. A PCAC recommendation is advisory. It does not itself make a peptide

Two separate studies on GLP-1 drugs and a rare eye condition were published within about a week of each other in late August 2026, and they reached different conclusions on the same specific question. That's not a contradiction to be resolved by picking the "right" one; it's a useful window into how much study design shapes what gets found in the first place. Key Takeaways Non-arteritic anterior ischemic optic neuropathy (NAION) is a rare condition caused by reduced blood flo

The FDA's July 2026 advisory committee vote on peptide compounding got most of the attention this year, but a quieter, more concrete story unfolded in parallel: the agency sending formal warning letters to specific online sellers. Five companies were cited together in the most recent round, and what they were actually selling is more revealing than the fact that letters were sent at all. Key Takeaways The FDA issued warning letters to five US-headquartered companies: Peak Per

Amgen's MariTide has been covered widely as "the monthly weight-loss shot," but that shorthand glosses over the specific trial generating the most useful data right now: MARITIME-SWITCH, a study testing whether people already doing well on weekly semaglutide or tirzepatide can transition to MariTide on a much less frequent schedule. The trial itself doesn't test monthly dosing at all. This piece covers what MARITIME-SWITCH actually measures, why the dosing interval matters, a

A new kind of peptide story emerged in late 2025 and has continued building through 2026: peptides designed not by studying natural biology, but by AI systems generating entirely novel amino acid sequences from scratch. One company reported its AI engine designed more than 5,000 novel candidates targeting a single receptor in 72 hours. That's a genuinely new category worth understanding, and it's also easy to overstate. This piece explains what "AI-designed peptide" actually

Interest in peptide-based hair treatments has a clear, traceable driver in 2026: the explosion in GLP-1 drug use has come with a documented side effect of hair loss for some users, and that's pushing a wave of new searches toward peptide-based regrowth options. This piece separates what's actually causing that hair loss, what peptide treatments have real supporting data, and what's still marketing riding on the broader "peptides fix everything" wave. Key Takeaways A UCSF stud

Multiple industry market reports published within days of each other in August 2026 all flagged the same thing: oral peptide delivery is growing faster than the broader peptide market containing it. That's a real trend worth explaining, but the reason it's taken this long to become one is itself the story. Peptides are proteins, and the digestive system's entire job is to break proteins apart. This piece covers what's actually been solved, what's still marketing ahead of the

A specific claim has been circulating in peptide-marketing content: that retatrutide produces meaningfully better results for women than for men, cited with precise-sounding numbers. When a claim comes with numbers that specific, it should be traceable to a real source. This one isn't, at least not to any source Eli Lilly or independent medical reporting has actually published. Here's what the actual disclosed trial data shows, and what it doesn't. Key Takeaways A specific cl

Search for menopause hormone optimization in 2026 and peptides show up constantly, usually listed alongside bioidentical estrogen, progesterone, and testosterone as if they belong to the same evidence tier. They don't. This piece audits what's actually being bundled into these programs, peptide by peptide, and checks each one against what's actually been established for it. Key Takeaways A 2026 compounding pharmacy resource listing “popular compounded medicines for hormone op

The FDA's July 2026 vote on peptide compounding wasn't about menopause at all, but menopause and midlife hormone specialists have started translating it for their own patients anyway, and some of that translation has been more careful than others. This piece walks through what the vote actually covered, what a menopause-focused clinician got right when she explained it to her own audience, and why "the FDA is opening up peptide access" is not the same claim as "the FDA review

Peptide therapy marketing aimed at women, and specifically at menopause and midlife, has expanded rapidly in 2026, with specialty clinics now publishing menopause-specific peptide guides and "best peptides for women over 50" lists. Much of this content bundles together compounds with wildly different evidence bases as though they were interchangeable. This piece works through what's actually documented for women specifically, including the one clear win in the human data, the

Self-injecting peptides has moved from a niche biohacking practice to a much more mainstream habit in 2026, and health authorities, medical associations, and Reddit communities are all documenting the same pattern: most of the real-world harm isn't coming from the peptides' pharmacology, it's coming from preparation and injection mistakes. This piece walks through what's actually going wrong, based on current clinical guidance and firsthand accounts, rather than theoretical r